Want to see HK:9877 full AI Analyst Report?
Jenscare Scientific Co. Ltd. Class H (9877) AI Stock Analysis
Jenscare Scientific Co. Ltd. Class H
(HKEX:9877)
The score is held back primarily by ongoing heavy losses and negative free cash flow, indicating the business is not yet financially self-sustaining despite improved revenue and strong gross margins. Low leverage supports balance-sheet resilience, while technicals are mixed (near-term stabilization but weaker longer-term trend). Valuation is difficult to assess with a negative P/E and no dividend yield data.
Jenscare Scientific Co. Ltd. Class H (9877) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.74B
- Dividend Yield
- ―
- Average Volume (3M)
- 41.24K
- Price to Earnings (P/E)
- -16.4
- Beta (1Y)
- 0.38
- Revenue Growth
- 992.68%
- EPS Growth
- 35.04%
- Country
- Hong Kong
- Employees
- 225
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Jenscare Scientific Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an in...
How the Company Makes Money
The company primarily makes money by selling its medical devices and associated procedural systems to healthcare providers and/or through distribution channels, generating revenue per unit sold (and, where applicable, per procedure supported by its p...
Jenscare Scientific Co. Ltd. Class H Financial Statement Overview
Summary
Revenue ramped sharply in 2025 with very strong gross margin (~75%), indicating promising unit economics and commercialization progress. However, profitability remains very weak (large operating losses and net loss ~264.2M) and cash flow is still negative (FCF about -80.1M), implying ongoing funding needs despite some improvement in cash burn. Balance sheet leverage is low (debt-to-equity ~0.06), which helps, but negative ROE (~-33%) highlights the current lack of earnings power.
Income Statement
28NegativeBalance Sheet
72PositiveCash Flow
34Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 140.08M | 88.24M | 0 | 0 | 0 | 0 |
| Gross Profit | 107.15M | 66.60M | 0 | 0 | 0 | 0 |
| EBITDA | -43.41M | -209.85M | 12.63M | -426.40M | -502.08M | -498.58M |
| Net Income | -148.71M | -264.21M | -177.51K | -371.74M | -439.31M | -500.52M |
Balance Sheet | ||||||
| Total Assets | 841.53M | 896.62M | 1.03B | 1.33B | 1.43B | 1.34B |
| Cash, Cash Equivalents and Short-Term Investments | 414.54M | 527.63M | 605.99M | 1.09B | 825.11M | 800.59M |
| Total Debt | 39.68M | 47.38M | 64.42M | 44.08M | 3.87M | 2.41M |
| Total Liabilities | 107.46M | 123.16M | 110.61M | 100.84M | 58.30M | 50.77M |
| Stockholders Equity | 750.42M | 789.75M | 931.76M | 1.23B | 1.37B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | -73.92M | -80.08M | -288.81M | -300.64M | -208.03M | -157.25M |
| Operating Cash Flow | -61.17M | -75.00M | -217.55M | -222.44M | -158.48M | -141.89M |
| Investing Cash Flow | 6.87M | 5.96M | 5.59M | 358.13M | -146.58M | -475.07M |
| Financing Cash Flow | -22.10M | -20.61M | -110.74M | 56.44M | 188.93M | 1.08B |
Jenscare Scientific Co. Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9877, the sentiment is Negative. The current price of 6.57 is below the 20-day moving average (MA) of 6.91, below the 50-day MA of 7.14, and below the 200-day MA of 7.99, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 38.97 is Neutral, neither overbought nor oversold. The STOCH value of 58.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9877.
Jenscare Scientific Co. Ltd. Class H Peers Comparison
Overall Rating
HK:178972Outperform
HK:150164Neutral
HK:223559Neutral
HK:130256Neutral- HK:987749Neutral
HK:999648Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1789 | 72Outperform | HKD 5.05B | 11.38 | 13.24% | 2.59% | 16.15% | 31.89% |
| HK:1501 | 64Neutral | HKD 6.34B | 21.57 | 9.64% | 0.87% | 34.94% | 12.99% |
| HK:2235 | 59Neutral | HKD 2.82B | 27.65 | 4.08% | ― | 94.80% | ― |
| HK:1302 | 56Neutral | HKD 6.35B | 98.22 | 1.71% | ― | 0.75% | -20.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9877 | 49Neutral | HKD 3.70B | -16.40 | -19.31% | ― | 992.68% | 35.04% |
| HK:9996 | 48Neutral | HKD 2.55B | -15.11 | -7.65% | ― | 21.23% | 36.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9877 | Jenscare Scientific Co. Ltd. Class H | 6.57 | -3.97 | -37.67% | |
| HK:9996 | Peijia Medical Ltd. | 3.77 | -2.22 | -37.06% | |
| HK:1302 | LifeTech Scientific Corporation | 1.47 | -0.58 | -28.29% | |
| HK:1501 | Shanghai Kindly Medical Instruments Co., Ltd. Class H | 30.00 | 0.12 | 0.39% | |
| HK:1789 | AK Medical Holdings Ltd. | 4.56 | -1.34 | -22.75% | |
| HK:2235 | MicroTech Medical (Hangzhou) Co., Ltd. Class H | 6.70 | -0.20 | -2.90% |
Jenscare Scientific Co. Ltd. Class H Corporate Events
Jenscare Wins NMPA Approval for JensClip, Accelerates Global Valve Portfolio Push
Jenscare Scientific has received registration approval from China’s National Medical Products Administration for its JensClip Transcatheter Mitral Valve Repair Clip System. The device features an innovative self-locking design, flexible shape a...
Jenscare Wins Hong Kong Approval for LuX-Valve Plus Valve System
Jenscare Scientific Co., Ltd., a China-based structural heart medical device maker, focuses on transvenous valve replacement systems such as LuX-Valve Plus for treating tricuspid regurgitation. The company targets major cardiovascular markets in Euro...
Jenscare Raises Caps on Connected Medical Device Accessories Deal
Jenscare Scientific has revised the annual caps under its Medical Devices Accessories Purchase Agreement with Linstant, a related party ultimately controlled by a substantial shareholder, after actual and expected transaction amounts were projected t...
Jenscare Scientific Delivers Strong Interim Growth as Structural Heart Portfolio Globalizes
Jenscare Scientific reported a sharp acceleration in its first full year of commercialization, with interim revenue for the six months to 30 June 2026 surging 377.7% year-on-year to RMB64.1 million and gross margin reaching 86.5%. The company substan...
Jenscare Scientific Schedules Board Meeting to Review 2026 Interim Results and Dividend Plan
Jenscare Scientific Co., Ltd. has scheduled a board meeting for August 31, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The board will also consider whether to...
Jenscare forecasts sharp interim revenue surge on heart device growth
Jenscare Scientific Co., Ltd., a mainland China-based medical device maker specializing in structural heart disease therapies, is seeing strong commercial traction for its Ken-Valve transcatheter aortic valve replacement system and related products....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 27, 2026